블로그
- Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in ... Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic
- Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Background
- bold-100 한눈 요약 Bold Therapeutics+1 그러나: 면역관문억제제(ICIs)나 CAR-T처럼 이미 확립된 생존(Overall Survival)·대규모 허가 근거를 가진 치료제들과는 검증 정도가
- Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival Background: Prior with colorectal cancer survival; however, few studies have considered the potentially distinct roles
- Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumor targeted therapies as well as immune checkpoint inhibitors has led to a substantial improvement in the overall survival of patients with NRAS wild-type tumors, current therapies for NRAS-mutant cancers are limited